AstraZeneca's High-level Results From Phase 3 OBERON and TITANIA Trials In Chronic Obstructive Pulmonary Disease Show Tozorakimab Reduced Annualised Rate Of Moderate-To-Severe Exacerbations Vs. Placebo - AstraZeneca (NYSE:AZN)
Published on March 27, 2026.
AristaZenica's results from the Phase 3 OBERON and TITANIA trials in which Tozorakimab was found to reduce the annual rate of exacerbations. The company is also working with the University of California, where it operates under the influence of the pharmaceutical industry.
Related Articles
Limits to wedding planning with AI
Over a third of engaged couples use AI for wedding planning, but can't guarantee a human-like outcome?
Surrogacy: Why it can cost more than $100K
Surrogacy can cost over $100,000 in the US, with limited insurance coverage and emotional conflicts affecting many individuals.
Florida Man Let ChatGPT Sell His Home. It Closed in 5 Days and Beat All Other Agents’ Estimates by $100,000
A Florida man successfully sold his home himself, using AI software, to raise $100,000, outperforming real estate agents’ estimates.